376 related articles for article (PubMed ID: 12296856)
1. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG
Clin Exp Immunol; 2002 Oct; 130(1):75-84. PubMed ID: 12296856
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.
Schafer PH; Gandhi AK; Loveland MA; Chen RS; Man HW; Schnetkamp PP; Wolbring G; Govinda S; Corral LG; Payvandi F; Muller GW; Stirling DI
J Pharmacol Exp Ther; 2003 Jun; 305(3):1222-32. PubMed ID: 12649301
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of MHC class I-stimulated alloresponses by TNF/TNF receptor (TNFR)1 interactions and of MHC class II-stimulated alloresponses by TNF/TNFR2 interactions.
Brown GR; Thiele DL
Eur J Immunol; 2000 Oct; 30(10):2900-7. PubMed ID: 11069072
[TBL] [Abstract][Full Text] [Related]
4. TNF regulates thymocyte production by apoptosis and proliferation of the triple negative (CD3-CD4-CD8-) subset.
Baseta JG; Stutman O
J Immunol; 2000 Nov; 165(10):5621-30. PubMed ID: 11067918
[TBL] [Abstract][Full Text] [Related]
5. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.
Corral LG; Haslett PA; Muller GW; Chen R; Wong LM; Ocampo CJ; Patterson RT; Stirling DI; Kaplan G
J Immunol; 1999 Jul; 163(1):380-6. PubMed ID: 10384139
[TBL] [Abstract][Full Text] [Related]
6. In vitro anti-inflammatory activity of Phlebodium decumanum. Modulation of tumor necrosis factor and soluble TNF receptors.
Punzón C; Alcaide A; Fresno M
Int Immunopharmacol; 2003 Sep; 3(9):1293-9. PubMed ID: 12890427
[TBL] [Abstract][Full Text] [Related]
7. TNFR1 delivers pro-survival signals that are required for limiting TNFR2-dependent activation-induced cell death (AICD) in CD8+ T cells.
Twu YC; Gold MR; Teh HS
Eur J Immunol; 2011 Feb; 41(2):335-44. PubMed ID: 21268004
[TBL] [Abstract][Full Text] [Related]
8. Selective down-regulation of T cell- and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone.
Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I
Immunol Lett; 1999 Jun; 68(2-3):325-32. PubMed ID: 10424439
[TBL] [Abstract][Full Text] [Related]
9. Interferon-gamma rescues TNF-alpha-induced apoptosis mediated by up-regulation of TNFR2 on EoL-1 cells.
Horie T; Dobashi K; Iizuka K; Yoshii A; Shimizu Y; Nakazawa T; Mori M
Exp Hematol; 1999 Mar; 27(3):512-9. PubMed ID: 10089914
[TBL] [Abstract][Full Text] [Related]
10. Properties of thalidomide and its analogues: implications for anticancer therapy.
Teo SK
AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
[TBL] [Abstract][Full Text] [Related]
11. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
Atreya R; Zimmer M; Bartsch B; Waldner MJ; Atreya I; Neumann H; Hildner K; Hoffman A; Kiesslich R; Rink AD; Rau TT; Rose-John S; Kessler H; Schmidt J; Neurath MF
Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
[TBL] [Abstract][Full Text] [Related]
12. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
Front Immunol; 2018; 9():583. PubMed ID: 29623079
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor.
Morel Y; Schiano de Colella JM; Harrop J; Deen KC; Holmes SD; Wattam TA; Khandekar SS; Truneh A; Sweet RW; Gastaut JA; Olive D; Costello RT
J Immunol; 2000 Oct; 165(8):4397-404. PubMed ID: 11035077
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner.
Payvandi F; Wu L; Haley M; Schafer PH; Zhang LH; Chen RS; Muller GW; Stirling DI
Cell Immunol; 2004 Aug; 230(2):81-8. PubMed ID: 15598423
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Herpesvirus saimiri-transformed T lymphocytes from common variable immunodeficiency patients.
Cabanillas JA; Cambronero R; Pacheco-Castro A; García-Rodríguez MC; Martín-Fernández JM; Fontán G; Regueiro JR
Clin Exp Immunol; 2002 Feb; 127(2):366-73. PubMed ID: 11876763
[TBL] [Abstract][Full Text] [Related]
17. CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production.
Marriott JB; Westby M; Cookson S; Guckian M; Goodbourn S; Muller G; Shire MG; Stirling D; Dalgleish AG
J Immunol; 1998 Oct; 161(8):4236-43. PubMed ID: 9780198
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents.
Marriott JB; Dredge K; Dalgleish AG
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Sep; 3(3):181-6. PubMed ID: 12871024
[TBL] [Abstract][Full Text] [Related]
19. Regulation of IL-15-stimulated TNF-alpha production by rolipram.
Kasyapa CS; Stentz CL; Davey MP; Carr DW
J Immunol; 1999 Sep; 163(5):2836-43. PubMed ID: 10453029
[TBL] [Abstract][Full Text] [Related]
20. Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF.
Ablamunits V; Bisikirska B; Herold KC
Eur J Immunol; 2010 Oct; 40(10):2891-901. PubMed ID: 21038470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
